News articles

News article list

• Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS

  Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.

• Thousands could benefit from new option for treating symptoms of uterine fibroids

  As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.

• Two new treatment options for incurable blood cancer assessed

  We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.

• World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England

  Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

• 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

  Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

• NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

  Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.